Surgery Partners (SGRY) to Release Quarterly Earnings on Monday

Surgery Partners (NASDAQ:SGRY) is anticipated to announce its earnings results before the market opens on Monday, February 24th. Analysts expect the company to announce earnings of $0.40 per share and revenue of $828.01 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Surgery Partners Trading Down 1.4 %

NASDAQ SGRY opened at $25.31 on Friday. The stock has a market capitalization of $3.22 billion, a P/E ratio of -52.73, a P/E/G ratio of 19.32 and a beta of 2.60. Surgery Partners has a 52-week low of $19.50 and a 52-week high of $34.10. The firm has a 50-day moving average price of $22.62 and a 200 day moving average price of $26.65. The company has a quick ratio of 1.66, a current ratio of 1.80 and a debt-to-equity ratio of 0.99.

Insider Transactions at Surgery Partners

In related news, CEO Jason Eric Evans sold 26,520 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $25.65, for a total transaction of $680,238.00. Following the sale, the chief executive officer now owns 560,698 shares in the company, valued at approximately $14,381,903.70. This trade represents a 4.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Harrison R. Bane sold 56,315 shares of the firm’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $25.64, for a total transaction of $1,443,916.60. Following the sale, the insider now owns 107,037 shares in the company, valued at approximately $2,744,428.68. This trade represents a 34.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 96,733 shares of company stock valued at $2,480,106 in the last ninety days. Corporate insiders own 2.30% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Macquarie reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Surgery Partners in a report on Tuesday, November 19th. JPMorgan Chase & Co. dropped their target price on shares of Surgery Partners from $38.00 to $28.00 and set a “neutral” rating for the company in a report on Tuesday, December 3rd. Royal Bank of Canada dropped their target price on shares of Surgery Partners from $49.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, November 20th. Finally, Bank of America assumed coverage on shares of Surgery Partners in a report on Monday, December 16th. They issued a “buy” rating and a $30.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Surgery Partners presently has an average rating of “Moderate Buy” and a consensus price target of $36.56.

About Surgery Partners

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.